Investors reject bid for sale to Genzyme
After rare loss, firm will extend $350m Bioenvision offer
Genzyme Corp. suffered an unaccustomed defeat yesterday when shareholders in Bioenvision Inc. , a small New York cancer-drug developer, blocked a $350 million takeover bid by refusing to sell their stock to the Cambridge biotechnology giant. (Full article: 603 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
